Article

OBJECTIVE: To assess changes in body composition, body weight and resting
metabolic rate in patients who received intrathecal baclofen therapy for
spasticity. DESIGN: Prospective, longitudinal, quasi-experimental, with a pre/post design. PATIENTS: Twelve patients with spasticity, fulfilling study
criteria, and due for pump implantation for intrathecal baclofen therapy,
completed the study.
METHODS: Data were obtained before, 6 months and 12 months
after commencement of intrathecal baclofen therapy as regards body composition
(by skinfold calliper), body weight, and resting metabolic rate (by resting
oxygen consumption).
Spasticity was assessed according to the Modified Ashworth
Scale (MAS) and Penn Spasm Frequency Scale (PSFS). RESULTS: A reduction in
spasticity according to MAS occurred. Mean fat body mass increased and mean lean
body mass decreased. Mean body weight showed a non-significant increase and
resting metabolic rate a non-significant decrease. CONCLUSION: This explorative
study indicates that unfavourable changes in body composition might occur after
intrathecal baclofen therapy. Since obesity and increased fat body mass
contribute to an increased cardiovascular risk, these findings may indicate a
need for initiation of countermeasures, e.g. increased physical activity and/or
dietary measures, in conjunction with intrathecal baclofen therapy. Further
studies, including larger study samples and control groups, are needed to
corroborate these findings.

Langue : ANGLAIS